The Hemophilia and Thrombosis Research Society (HTRS) bestowed its Lifetime Achievement Award on long-time researcher and clinician Louis M. Aledort, MD. He received the award at the HTRS and North American Specialized Coagulation Laboratory Association Scientific Symposium on Friday, April 16, 2010, in Chicago, IL.
Aledort, who is the The Mary Weinfeld Professor of Clinical Research in Hemophilia at Mount Sinai School of Medicine in NYC, was given the award in recognition of his distinguished career and outstanding contributions to the field of blood disorders. Aledort was nominated for the award by Cindy Leissinger, MD, Professor of Medicine, Pediatrics, and Pathology, and Chief of the Section of Hematology & Medical Oncology, Tulane University School of Medicine in Louisiana.
Considered a groundbreaker in the field of coagulation disorders, Aledort concentrated on the safety and efficacy of bleeding disorder therapies, bleeding related to blood thinning drugs and on idiopathic thrombocytopenic purpura, a platelet disorder. His work helped enhance research standards and patient care.
Aledort has been a leader in designing and implementing several innovative collaborative study groups, such as the U.S. Hemophilia Study Group, the Transfusion Safety Study and the Orthopedic Outcome Study. “What stands out to many of his colleagues and students is Dr. Aledort's commitment to education and collaborative research,” said Leissinger. “He provides opportunities for partnership on projects of scientific interest and importance, while fostering and encouraging rigorous academic debate. His counsel has had far-reaching effects and shaped the professional hemophilia community today.”
Aledort has authored more than 400 peer-reviewed articles in leading scientific journals, including the Journal of Thrombosis and Haemostasis, The Lancet, The New England Journal of Medicine and Haemophilia.
Source: Mount Sinai Medical Center press release dated April 21, 2010